Reaction
Lymphocytic Infiltration reporting signals
As of the last recalculation, Lymphocytic Infiltration appears in 981 FAERS reports alongside 19 co-occurring drug terms. The strongest observed disproportionality signal is BASILIXIMAB (PRR 46.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Basiliximab | 25 | 46.3 | 46.4 |
| Anti-Thymocyte Globulin (Rabbit) | 8 | 21.2 | 21.2 |
| Tenofovir Disoproxil Fumarate Tablets | 8 | 19.8 | 19.8 |
| Gentamicin | 11 | 18.0 | 18.0 |
| Lamivudine Oral | 21 | 18.0 | 18.0 |
| Daspone | 8 | 17.6 | 17.6 |
| Dapsone Gel, 5% | 8 | 17.6 | 17.6 |
| Imatinib | 14 | 17.1 | 17.1 |
| Nevirapine | 7 | 16.6 | 16.6 |
| Bleomycin Sulfate | 8 | 16.6 | 16.6 |
| Gentamicin Sulfate | 12 | 16.3 | 16.3 |
| Dapsone | 8 | 16.0 | 16.0 |
| Zidovudine | 10 | 16.0 | 16.0 |
| Lamivudine | 22 | 15.4 | 15.4 |
| Raltegravir | 9 | 11.7 | 11.7 |
| Tenofovir Disoproxil Fumarate | 17 | 11.1 | 11.1 |
| Ranitidine Hydrochloride | 21 | 8.4 | 8.4 |
| Eltrombopag Olamine | 9 | 8.3 | 8.4 |
| Dupilumab | 55 | 2.5 | 2.5 |